WASHINGTON (dpa-AFX) - RXi Pharmaceuticals Corp. (RXII) said it licensed worldwide rights to develop and commercialize a Folate Binding Protein-E39, or FBP, targeted vaccine to prevent recurrence in gynecological cancers such as ovarian and endometrial adenocarcinomas.
The FBP vaccine consists of the E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor. FBP is over-expressed in more than 90% of ovarian and aggressive endometrial cancers, as well as 20-50% of breast, lung, colorectal and renal cell carcinomas.
Markb Ahn, chief executive officer and president of RXi Pharma, stated, 'Licensing FBP which is already IND- and IRB- approved, and ready to commence two Phase 1 clinical trials in ovarian/endometrial and breast cancers, doubles our pipeline and further advances RXi's leadership in cancer immunotherapy. We anticipate initiation of clinical trials this year and are excited about exploring the promising potential of the FBP vaccine in critical areas of unmet medical need.'
Copyright RTT News/dpa-AFX
